Tumor Genomic Profiling denied due to quantity / dose limits by Avalon Healthcare Solutions?

Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.

Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.

## Why Avalon Healthcare Solutions Limits Tumor Genomic Profiling — and Why You Can Appeal

Tumor genomic profiling (comprehensive genomic sequencing or panel-based molecular testing) gives oncologists a detailed map of the mutations driving a cancer, enabling targeted therapy decisions. Avalon Healthcare Solutions, which manages laboratory benefit programs for many health plans, enforces quantity-limit policies that typically restrict how often — and under what clinical circumstances — a comprehensive genomic test can be approved for the same patient.

### Why This Denial Happens

Quantity-limit denials on genomic profiling most often occur because the plan has already approved one test for this patient, or because the request covers a test type or tissue source that Avalon's medical policy treats as duplicative of a prior result. The limit is usually tied to a per-cancer or per-episode rule written into the laboratory benefit management program. These restrictions exist because payers treat broad genomic sequencing as a high-cost service that should be used selectively — but clinical reality often demands re-testing when a tumor progresses, histology changes, or a new tissue specimen becomes available.

### Why It Is Appealable

A quantity-limit denial is a coverage determination, not a final word. When clinical circumstances justify a repeat or additional test — such as disease progression, a new metastatic site, or a change in treatment strategy — the denial is often overturnable on appeal. The key is demonstrating that this test is clinically distinct from any prior test and that the result will directly change management.

### Federal Appeal Framework

• Internal appeal: Submit within the timeframe printed on your denial notice (typically 180 days for ACA-compliant plans). The plan must respond within 30 days for pre-service and 60 days for post-service claims.
• External review (ACA §2719): If the internal appeal is denied, you have the right to an independent external review. For most ACA-compliant and self-funded ERISA plans, you generally have approximately four months from the internal denial to file. An accredited Independent Review Organization (IRO) — not the insurer — makes the final binding decision.
• ERISA §503: For employer-sponsored plans, ERISA requires a full-and-fair review of every adverse benefit determination. An ERISA attorney can compel disclosure of the full administrative record.
• Expedited review: If delaying treatment while awaiting a result would seriously jeopardize health, request an expedited appeal. Decisions are typically required within 72 hours.

### Documentation to Gather

1. Current diagnosis confirmation — pathology report confirming cancer type, stage, and histology at the time of this request. 2. Prior test records — dates, panel name, results, and tissue source of any prior genomic tests, with a clear clinical explanation of why those results do not answer the current clinical question. 3. Clinical rationale for re-testing — chart notes documenting disease progression, new biopsy site, change in treatment intent, or another distinct clinical event. 4. Prescriber medical-necessity letter — a signed letter from the ordering oncologist explaining why a new test is necessary, what clinical question it will answer, and how the result will change the treatment plan. 5. Applicable guideline reference — your oncologist should cite the relevant NCCN guideline category or equivalent society guidance supporting genomic testing in this clinical scenario (without relying on specific policy numbers).

### Criteria-Mapping Structure

Pull the exact requirements from Avalon's published laboratory benefit management policy for comprehensive genomic profiling. Then build a side-by-side table: each policy requirement in the left column, the specific chart documentation that satisfies it in the right column. Attach that table as a cover sheet to your appeal packet. This structure forces the reviewer to address each criterion individually and makes it far harder to issue a blanket denial.